Multiple sclerosis management during the COVID-19 pandemic
Moss, Brandon P. (Mellen Center for Multiple Sclerosis, Cleveland Clinic)
Mahajan, Kedar R. (Mellen Center for Multiple Sclerosis, Cleveland Clinic)
Bermel, Robert (Mellen Center for Multiple Sclerosis, Cleveland Clinic)
Hellisz, Kelsey (Mellen Center for Multiple Sclerosis, Cleveland Clinic)
Hua, Le H. (Lou Ruvo Center for Brain Health, Cleveland Clinic)
Hudec, Timothy (Mellen Center for Multiple Sclerosis, Cleveland Clinic)
Husak, Scott (Mellen Center for Multiple Sclerosis, Cleveland Clinic)
McGinley, Marisa P. (Mellen Center for Multiple Sclerosis, Cleveland Clinic)
Ontaneda, Daniel (Mellen Center for Multiple Sclerosis, Cleveland Clinic)
Wang, Zhini (Department of Quantitative Health Sciences, Cleveland Clinic)
Weber, Malory (Mellen Center for Multiple Sclerosis, Cleveland Clinic)
Tagliani, Paula (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Cárdenas-Robledo, Simón (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Zabalza, Ana (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Arrambide, Georgina (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Carbonell-Mirabent, Pere (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Rodríguez-Barranco, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Sastre-Garriga, Jaume (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Tintoré, Mar (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Montalban, Xavier (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Douglas, Morgan (Division of Neuroimmunology and Neurological Infections, Johns Hopkins University)
Ogbuokiri, Esther (Division of Neuroimmunology and Neurological Infections, Johns Hopkins University)
Aravidis, Berna (Division of Neuroimmunology and Neurological Infections, Johns Hopkins University)
Cohen, Jeffrey A. (Mellen Center for Multiple Sclerosis, Cleveland Clinic)
Mowry, Ellen M. (Division of Neuroimmunology and Neurological Infections, Johns Hopkins University)
Fitzgerald, Kathryn C. (Division of Neuroimmunology and Neurological Infections, Johns Hopkins University)
Universitat Autònoma de Barcelona

Fecha:	2020
Resumen:	People with multiple sclerosis (MS) may be at higher risk for complications from the 2019 coronavirus (COVID-19) pandemic due to use of immunomodulatory disease modifying therapies (DMTs) and greater need for medical services. To evaluate risk factors for COVID-19 susceptibility and describe the pandemic's impact on healthcare delivery. Surveys sent to MS patients at Cleveland Clinic, Johns Hopkins, and Vall d'Hebron-Centre d'Esclerosi Múltiple de Catalunya in April and May 2020 collected information about comorbidities, DMTs, exposures, COVID-19 testing/outcomes, health behaviors, and disruptions to MS care. There were 3028/10,816 responders. Suspected or confirmed COVID-19 cases were more likely to have a known COVID-19 contact (odds ratio (OR): 4. 38; 95% confidence interval (CI): 1. 04, 18. 54). In multivariable-adjusted models, people who were younger, had to work on site, had a lower education level, and resided in socioeconomically disadvantaged areas were less likely to follow social distancing guidelines. 4. 4% reported changes to therapy plans, primarily delays in infusions, and 15. 5% a disruption to rehabilitative services. Younger people with lower socioeconomic status required to work on site may be at higher exposure risk and are potential targets for educational intervention and work restrictions to limit exposure. Providers should be mindful of potential infusion delays and MS care disruption.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	COVID-19 ; SARS-CoV-2 ; Multiple sclerosis ; Disease modifying therapies ; Health behaviors ; Healthcare delivery
Publicado en:	Multiple sclerosis, August 2020, ISSN 1477-0970

DOI: 10.1177/1352458520948231
PMID: 32772807

9 p, 776.0 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados